The submission was based on data from the double-blind, placebo-controlled VOYAGE trial.
Your search for oral corticosteroids returned 12 results
The FDA has approved a prefilled pen formulation of Dupixent (dupilumab; Sanofi and Regeneron), providing another option for administering the treatment.
Updated on 6/16 While no specific treatment for coronavirus disease 2019 (COVID-19) is currently available, several therapies are being investigated globally.* AB201 (ARCA biopharma): a selective inhibitor of tissue factor being developed as a potential treatment for COVID associated coagulopathy. Clinical testing is expected to begin in the second half of 2020. Acalabrutinib (AstraZeneca): a…
The American College of Allergy, Asthma and Immunology (ACAAI) has issued a statement regarding the use of corticosteroids for patients with allergies and asthma.
The FDA has approved ArmonAir® Digihaler (fluticasone propionate; Teva) for the maintenance treatment of asthma as prophylactic therapy in patients 12 years of age and older.
Treatment with masitinib, a selective tyrosine kinase inhibitor, significantly reduces the rate of severe asthma exacerbations in patients with severe asthma uncontrolled by oral corticosteroids, according to data from a phase 3 study.
Rituximab was found to be superior to mycophenolate mofetil (MMF) in adult patients with severe pemphigus vulgaris, according to new phase 3 trial data.
This article is part of MPR’s coverage of the American Academy of Ophthalmology 2019 Meeting, taking place in San Francisco, CA. Our staff will report on medical research related to eye disorders, conducted by experts in the field. Check back regularly for more news from AAO 2019. SAN FRANCISCO – For patients with progressive Acanthamoeba…
Treatment with mepolizumab was associated with a significant reduction in asthma exacerbations and oral corticosteroid use in patients with severe eosinophilic asthma.
New exploratory data published in the New England Journal of Medicine further provide evidence of the benefits of vedolizumab (Entyvio; Takeda), an integrin receptor antagonist, when compared with adalimumab (Humira; AbbVie), a tumor necrosis factor-alpha (TNFα) antagonist, in patients with moderately to severely active ulcerative colitis. In the phase 3b VARSITY study, patients were randomized…